Dr.Β ManishΒ Shah
BSE, MD, FASCO
Bartlett Family Professor in Gastrointestinal Oncology
corporate_fareWeill Cornell Medicine / NewYork-Presbyterian, New York
Manish Shah
BSE, MD, FASCO
Dr. Manish A. Shah is the Bartlett Family Professor in Gastrointestinal Oncology and Director of the GI Oncology Program at Weill Cornell Medicine / NewYork-Presbyterian in New York City. He is one of the most widely recognised experts in gastric, gastroesophageal junction, and esophageal cancer in the United States, with over 25 years of clinical and research experience.
Dr. Shah trained at Johns Hopkins University, Harvard Medical School and MIT, and completed his Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, where he served as Chief Oncology Fellow. He joined Weill Cornell Medicine in 2011 after a decade as Attending Physician at Memorial Sloan Kettering. His career has focused on improving outcomes in upper GI tract malignancies through clinical trials, drug development, and translational research. He led the landmark KEYNOTE-811 Phase III trial demonstrating that adding pembrolizumab to trastuzumab and chemotherapy significantly improves survival in HER2-positive gastric cancer, directly contributing to a new FDA-approved standard of care. He has also played a leading role in the GLOW trial of zolbetuximab for CLDN18.2-positive gastric cancer. With over 350 peer-reviewed publications and leadership of multiple Phase I, II and III trials, Dr. Shah chairs several ASCO guideline panels on gastroesophageal cancer management.
CancerFax can coordinate medical-record review and consultation support for international patients seeking an expert opinion or second opinion from Dr. Shah at Weill Cornell Medicine, subject to hospital availability and case acceptance.
Why Consider Dr. Manish A. Shah?
Dr. Shah is a nationally and internationally recognised thought leader in gastrointestinal oncology who has personally shaped current treatment standards for gastric and esophageal cancers through landmark clinical trial leadership and guideline authorship.
Areas of Specialisation
Upper gastrointestinal oncology, precision medicine, and advanced systemic therapy
Dr. Shah's clinical and research focus centres on gastric, gastroesophageal junction, and esophageal cancers, with particular expertise in HER2-targeted therapy, CLDN18.2-targeted therapy, immunotherapy, and genomic approaches to treatment selection.
Gastric & Gastroesophageal Junction Cancer
Comprehensive management of gastric and GEJ cancers including advanced and metastatic disease.
- arrow_rightTrastuzumab-based combination regimens for HER2-positive gastric cancer
- arrow_rightPembrolizumab plus trastuzumab plus chemotherapy per KEYNOTE-811 data
- arrow_rightHER2 biomarker testing guidance and treatment sequencing
- arrow_rightZolbetuximab-based therapy for CLDN18.2-positive gastric and GEJ adenocarcinoma
- arrow_rightPatient selection based on CLDN18.2 expression testing
- arrow_rightPembrolizumab (PD-1 blockade) for eligible gastric and GEJ cancer patients
- arrow_rightPD-L1 and biomarker-guided patient selection
Esophageal Cancer
Treatment planning for locally advanced and metastatic esophageal carcinoma.
- arrow_rightCombination chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer
- arrow_rightIntegration of immunotherapy per emerging KEYNOTE-975 trial data
- arrow_rightFOLFOX and CAPOX chemotherapy regimens
- arrow_rightTargeted and immune checkpoint-based approaches for advanced disease
Broader Gastrointestinal Oncology
Additional clinical expertise across gastrointestinal malignancies.
- arrow_rightSystemic treatment planning for colorectal cancer including FOLFOX regimens
- arrow_rightMedical oncology management of pancreas, liver, biliary tract, and small bowel cancers
- arrow_rightMultidisciplinary care coordination with surgical and radiation oncology teams
- arrow_rightClinical management of gastrointestinal neuroendocrine carcinomas
- arrow_rightTreatment planning based on grade, stage, and molecular profile
Procedures Performed
Clinical treatment approaches and services offered
Dr. Shah provides comprehensive medical oncology services for gastrointestinal cancers, including systemic therapy, clinical trial enrolment, multidisciplinary treatment planning, and second opinion consultations.
Systemic Cancer Treatment
Medical OncologyChemotherapy, immunotherapy, and combination regimens for gastric, GEJ, esophageal, and other GI cancers.
Targeted Therapy
Targeted TherapyBiomarker-guided targeted treatment including HER2 and CLDN18.2 directed therapies.
Multidisciplinary Treatment Planning
MultidisciplinaryCoordinated care with surgical oncology, radiation oncology, gastroenterology, and radiology teams.
Second Opinion Consultations
Second OpinionExpert second opinion review for patients with gastric, GEJ, esophageal, and other GI cancers.
Research & Publications
Landmark clinical trials and peer-reviewed contributions in gastrointestinal oncology
Dr. Shah has authored over 350 peer-reviewed publications and led multiple Phase I, II, and III clinical trials in advanced gastric and esophageal cancer. His work has directly contributed to FDA-approved treatment standards for HER2-positive and CLDN18.2-positive gastric cancer.
Dr. Shah is a peer-review funded investigator and prolific academic oncologist. A full publication list is available on PubMed and Google Scholar.
Education & Training
Dr. Shah trained at Johns Hopkins University, Harvard Medical School and MIT, Duke University Medical Center, and Memorial Sloan Kettering Cancer Center, where he completed his medical oncology fellowship as Chief Oncology Fellow.
Clinical Experience
Dr. Shah spent a decade as Attending Physician and Assistant Member at Memorial Sloan Kettering Cancer Center before being recruited to Weill Cornell Medicine in 2011. He has served as Director of the GI Oncology Program and Chief of the Solid Tumor Service since joining Weill Cornell.
Languages & International
Dr. Shah consults in the following language.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Shah.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Manish Shah
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Manish Shah's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Manish Shah's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Manish Shah before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Manish Shah's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Manish Shah's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Manish Shah's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Manish A. Shah
Dr. Shah specialises in gastric cancer (stomach cancer), gastroesophageal junction (GEJ) cancer, and esophageal cancer, with additional expertise in colorectal, pancreas, liver, biliary tract, and neuroendocrine cancers. His primary research and clinical focus is on upper GI malignancies, particularly HER2-positive and CLDN18.2-positive gastric and GEJ cancer.
KEYNOTE-811 is a landmark Phase III clinical trial led by Dr. Shah that evaluated the addition of pembrolizumab (a PD-1 immune checkpoint inhibitor) to trastuzumab and chemotherapy in patients with HER2-positive gastric and GEJ adenocarcinoma. The trial demonstrated significantly improved outcomes and contributed to a new FDA-approved treatment standard for this patient population. Dr. Shah served as Principal Investigator.
NewYork-Presbyterian and Weill Cornell Medicine welcome international patients and offer teleconsultation, second opinion, and treatment planning services. CancerFax can help coordinate medical-record review and consultation support for eligible international patients, subject to hospital availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging studies, treatment history, and relevant biomarker or molecular test results. The CancerFax team will organise the documentation and coordinate the next steps with the hospital, subject to availability. You may also contact the Weill Cornell GI Oncology Program directly at (646) 962-6200.
Dr. Shah's treatment approach for gastric and GEJ cancer includes HER2-targeted therapy with trastuzumab, pembrolizumab-based immunotherapy, CLDN18.2-targeted therapy with zolbetuximab, and standard chemotherapy regimens including FLOT, FOLFOX, and CAPOX. Treatment selection is guided by biomarker results including HER2 status, PD-L1 expression, CLDN18.2 expression, and other molecular markers.
Submit your medical reports through the CancerFax upload portal. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the hospital, subject to availability. For direct hospital contact, the Weill Cornell GI Oncology Program can be reached at (646) 962-6200, 1305 York Avenue, 12th Floor, New York, NY 10021.
Connect with Manish Shah Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.